Untersuchungen zum Einfluß der Urämie auf die Metabolisierung von Phenylbutazon und Aminophenazon beim Menschen

Summary 20 uremic patients with normal liver function received a single oral load of either 6 mg Phenylbutazone/kg or 12 mg Aminophenazone/kg body weight. Subsequently, the decay of plasma concentrations and plasma half-lifes of both drugs were estimated. The results were compared with the values ob...tained in control groups showing normal kidney and liver functions. 24 hr after treatment with Phenylbutazone, uremic patients had an average plasma concentration of 1.75±0.91 mg Phenylbutazone/100 ml, compared to 4.3±0.85 mg/100 ml in controls. In the latter, the plasma half-life of Phenylbutazone corresponded to 50.9±13.5 hr, while in uremic patients plasma half-life was approximately 48% higher (75.4±12.8 hr). 4 hr after the administration of Aminophenazone, the same plasma concentrations (1.03±0.45 mg/100 ml and 0.99±0.31 mg/100 ml, respectively) were observed in uremic patients and the control group. In uremic patients, Aminophenazone plasma half-life was 4.1±1.6 hr compared to 4.0±1.7 hr in control subjects. Plasma half-lifes of Aminophenazone and Phenylbutazone were not correlated to the urea and creatinine serum concentrations measured. Both drugs are eliminated by degradation in the liver endoplasmic reticulum through the mixed function oxydation pathway. It is therefo Ausführliche Beschreibung Beschreibung ausblenden

1. Person:	Leber, H. W.
Weitere Personen:	Harders, A.; Schütterle, G.
Quelle:	in Journal of molecular medicine Vol. 50 (1972), p. 1092-1096 Weitere Artikel
Format:	Online-Artikel
Genre:	Uremia, liver function, lipophilic drugs, Phenylbutazone, Aminophenazone, Urämie, Leberfunktion, lipophile Pharmaka, Phenylbutazon, Aminophenazon
Sprache:	German
Veröffentlicht:	1972
Beschreibung:	Online-Ressource
Online Zugang:	Online
Tags:	Hinzufügen Keine Tags. Fügen Sie den ersten Tag hinzu!
Anmerkung:	Copyright: Copyright 1972 Springer-Verlag